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Nitric oxide: biosynthesis and 
biological significance 
Michael A. Marietta 
The recent discovery that mammal ian  cells" can synthes ize  nitric oxide coincided 
with the identification o f  this s imple  gas as a fac tor  involved in cellular communica-  
tion. Nitric oxide has now been shown to be derived f r o m  L-arginine in macro-  
phages,  endothelial cells" and poss ibly  other cell types. Its physiological  role in 
macrophages  may  be as a cytotoxic agent. However ,  nitric oxide produced  by 
endothelial cells is thought  to trigger vascular smoo th  muscle  relaxation through 
activation o f  the e n z y m e  guanylate cyclase. 
The  s tudy of  wha t  a p p e a r e d  to be qui te  
d iverse  physiologica l  reac t ions  led to 
the  d iscovery  of  ni t r ic  oxide  ( . N = O )  as 
a m a m m a l i a n  me tabo l i t e  that  p lays  a 
cri t ical  role in ce l lu lar  commun ica t i on  
as well as o the r  i m p o r t a n t  funct ions.  
The  inves t iga t ion  of  the  a p p a r e n t  syn- 
thesis  of  n i t ra te  ( N O q )  by m a m m a l i a n  
cells r evea led  that ,  in m a c r o p h a g e s ,  
• N = O  was an i n t e rmed ia t e  in the  p ro-  
duct ion  of  bo th  NO,~ and ni t r i te  ( N O ~ )  
f rom L-arginine.  In qui te  un re l a t ed  
expe r imen t s ,  a fac tor  p r o d u c e d  by 
endo the l i a l  cells was shown to be 
r equ i r ed  for  the ace ty lcho l ine - induced  
re laxa t ion  of  vascular  smoo th  muscle.  
This fac tor  has now been  ident i f ied  as 
• N = O ,  also de r ived  f rom L-arginine.  
This review will summar i ze  these  init ial  
s tudies  that  led to the  ident i f ica t ion  of  
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• N = O  as a me t a bo l i t e  and  examine  its 
b iochemica l  synthesis  and poss ib le  bio- 
logical  funct ion.  A n o t h e r  recen t  rev iew 
by M o n c a d a  and co l leagues  I e m p h a -  
sizes the  regu la t ion  of  cell funct ion and 
communica t i on .  
It is ra re  to find such a reac t ive  mol-  
ecule  as a free i n t e r m e d i a t e  in mam-  
mal ian  b iochemis t ry .  The  chemis t ry  of  
• N = O  has been  s tud ied  a g rea t  dea l  
a l though not  typical ly  unde r  b io logica l  
condi t ions .  Nitr ic  oxide  reacts  read i ly  
with mo lecu la r  oxygen  in the  gas phase  
and in aqueous  so lu t ion  to yield ni t ro-  
gen d ioxide  (NO2) which is also reac-  
t ive and u l t imate ly  reacts  to form N O 2  
and N O 3  via the  hydro lys i s  of  N203 and 
N204.  The  role of  . N = O  as an enzyme-  
b o u n d  i n t e r m e d i a t e  in the  r educ t ion  of  
N O  2 by anae rob ic  deni t r i fy ing  bac te r i a  
has been  d e m o n s t r a t e d  by Ho l loche r  
and co -worke r s  over  the  last severa l  
years  2, however ,  as will be  desc r ibed  
be low,  the  m a m m a l i a n  pa thway  for 
• N = O  is qui te  dist inct  f rom the bac-  
ter ia l  reduc t ive  pa thway .  
0~) 1989. Elsevier Science Publishers Ltd. (UK) [~376 5067/89/$02.00 
Macrophage synthesis of NO~ and 
NO~ 
The  first me tabo l i c  ba lance  s tudies  
cons is ten t  with m a m m a l i a n  synthesis  of 
N O ~  were  car r ied  out  at the  turn of  the 
cen tury  (see Ref.  3 and re fe rences  
there in) .  R e n e w e d  in teres t  in NO,~ 
synthesis  in humans  s t e m m e d  f rom the 
po ten t i a l  for the  fo rma t ion  of  carcino-  
genic N-n i t rosamines  using this meta-  
bo l i ca l ly -de r ived  NO`q as a reac tant .  
The  e n d o g e n o u s  fo rma t ion  of  N- 
n i t rosamines  has been  under  invest iga-  
t ion for abou t  the last 20 years  and  the 
condi t ions  that  could  lead  to the  reac- 
t ion of  s econda ry  amines  with N O 2  
have been  well  s tud ied  3. Previous ly ,  
exposu re  to NO,~ was always p r e s u m e d  
to be  that  f rom env i ronmen ta l  sources .  
T a n n e n b a u m  and co -worke r s  3 first 
showed  that  N O 7  synthesis  was indeed  
a m a m m a l i a n  process .  They  found  that  
humans  and rats ,  when ma in t a ined  on a 
low N O 3  diet  ( - -  180 lamol day  - I  for 
humans ) ,  exc re ted  levels well above  
the inges ted  amount .  Similar  resul ts  
were  o b t a i n e d  with ge rm-f ree  rats ,  thus 
rul ing out  the  pa r t i c ipa t ion  of gut 
microf lora  in the  react ion .  Dur ing  the 
course  of  the h u m a n  e xpe r imen t s ,  one 
of  the subjec ts  co inc iden ta l ly  became  
ill and  showed a large increase  in urin- 
a ry  N O 3  excre t ion .  Subsequen t  exper -  
iments  in rats  showed  that  the  ur inary  
N O 3  levels could  be e l eva ted  abou t  
t enfo ld  when  fever  was induced  by an 
in t r ape r i t onea l  in jec t ion  of  E. coli l ipo- 
po lysacchar ide  (LPS)  3. These  findings 
sugges ted  that  this e l eva ted  synthesis  
might  be re la ted  to the i m m u n o s t i m u -  
la t ion known  to be b rough t  abou t  by 
LPS.  
The  s tudies  above  sugges ted  a po ten-  
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tial origin of NO3 synthesis and, 
perhaps more importanlly, an ex- 
perimental approach to the problem. 
Studies carried out with inbred strains 
of mice which had been characterized 
with defects in either T cells, B cells or 
macrophages suggested that after 
immunostimulation, the aaacrophage 
was responsible for this increase in 
NO3 synthesis 4. This LPS-induced syn- 
thesis in vivo was then reproduced by 
treatment of murine peritoneal macro- 
phages in culture 4. LPS-treated macro- 
phages typically synthesized about 150 
nanomoles per 106 cells per 24 hours 4. 
Further in vivo studies showed that 
strong immunostimulant.s such as 
Bacillus Calmette-Guerin increased 
urinary NO3 excretion in mice up to 
50-fold 4, suggesting that endogenous 
lymphokines could also stimulate 
macrophages to carry out this syn- 
thesis. Subsequent experiments showed 
that a major lymphokine involved 
in this response was interferon-7 
(IFN-¥) 5. The stimulatory effects of 
LPS and IFN- 7 were synergistic 5 and a 
number of murine macrophage cell 
lines were found to respond in a similar 
fashion to LPS and IFN-7 ~. 
Further studies with the RAW 264.7 
macrophage cell line showed that the 
chemical precursor to NO~ and NO~ 
was exclusively the amino acid 
L-arginine which was converted to 
citrulline 7. Experiments carried out 
with L-[guanidino-15Nz]-arginine un- 
equivocally showed that the nitrogen 
atoms of both NO2 and NO3 were 
derived solely from one of the two 
chemically equivalent ~SN-labeled ni- 
trogens 7. Initially it was assumed that 
the NO~ resulted from the oxidation of 
NO2 but experiments suggested that 
both anions were derived from a com- 
mon intermediateS; experiments with 
L-[guanidino-15N2]-arginine showed 
that .N=O was labeled s'9. The forma- 
tion of NO2 and NO~ was specific for 
the L (S) stereochemistry at the a-car- 
bon of arginine 7. Hibbs anet co-workers 
had been studying the cytostasis in 
certain tumor target cells induced 
by co-culture with activated macro- 
phages. They found that this 
cytostatic-inducing property required 
L-arginine in the cell culture medium l°, 
and they showed, using unlabeled 
L-arginine, that activated macrophages 
synthesized N02 and citrulline from 
L-arginine 11. 
Endothelium-derived relaxing factor 
(EDRF) 
In 1980, Furchgott and Zawadzki 
showed that endothelial cells were 
required for the acetylcholine-induced 
relaxation of vascular smooth muscle. 
A number of substances are now 
known that lead to the release of 
endothelium-derived relaxing factor 
(EDRF),  including adenine nucleo- 
tides, calcium ionophores and brady- 
kinin. The major pharmacological 
properties of EDRF are smooth muscle 
relaxation in a number of different 
vascular preparations and the inhibi- 
tion of platelet aggregation ~2, ~3. Specu- 
lation about the structure of EDRF 
continued until 1986 when Furchgott 
and Ignarro suggested that it might in 
fact be .N=O.  Experiments carried out 
by Moncada and colleagues 14 showed 
that EDRF was indeed .N=O.  Using a 
bioassay consisting of a strip of smooth 
muscle superfused by effluent from a 
column containing porcine aortic endo- 
thelial cells immobilized on micro- 
carriers, they showed that release of 
EDRF from bradykinin-stimulated 
cells led to relaxation in the strip of 
smooth muscle. A number of indirect 
experiments showed the structure of 
EDRF was consistent with the chemi- 
cal properties of .N=O.  Then, using 
chemiluminescence detection, they di- 
rectly observed the formation of-N = O. 
This finding has been reproduced now 
by several laboratories. Moncada and 
colleagues next showed that the precur- 
sor to .N=O was L-arginine ~5, suggest- 
ing an identical pathway to that 
characterized in macrophages. There is 
some evidence that polybasic polypep- 
tides containing L-arginine can serve as 
substrates for EDRF generation but it 
is not clear if these alternate substrates 
serve simply as metabolic precursors to 
L-arginine. The identification of .N=O 
as EDRF suggests a mechanism of 
action for the vasodilatory drugs such 
as amyl nitrite and nitroglycerin. Used 
since the 19th century, these com- 
pounds will produce .N=O in the pres- 
ence of thiols such as glutathione 
thereby circumventing the generation 
of .N=O from L-arginine. 
Biosynthesis of.N=O 
General characteristics 
While the pathway itself appears to 
be identical in macrophages and endo- 
thelial cells, its regulation in the two 
cell types is quite different. In macro- 
phages no enzymatic activity is ob- 
served in either freshly isolated, 
thioglycolate-elicited peritoneal cells 
or in any of the macrophage cell lines 
examined without activation by LPS 
and/or IFN-74-6. A lag phase that is 
dependent on the concentration of the 
activating agent(s) is observed during 
which time protein synthesis required 
for the expression of the pathway takes 
place. After the lag phase that is typi- 
cally about eight hours, the synthesis of 
NO~ and NO3 begins and continues 
linearly for about 48 hours after which 
time cell death leads to a decreased rate 
of synthesis 6. The similarity of freshly 
isolated cells and cell lines has been 
demonstrated and we have made use of 
cell lines extensively, in particular the 
RAW 264.7 line that is both quantitat- 
ively and qualitatively identical to 
freshly isolated cells 6. In the cell-free 
system described below the synthesis of 
• N = O ,  and consequently NO2 and 
NOq, continues as long as the sub- 
strates are available s. 
The situation in endothelial cells is 
very different. Protein synthesis is 
apparently not required. Stimulation 
by, for example, bradykinin, leads to 
an immediate burst in .N=O synthesis 
which decays rapidly 14. When 1-2 × 
107 cells were stimulated with brady- 
kinin at 10 min intervals, the amounts 
produced (< 1 nmoi) are small relative 
to those produced in the macrophage 
but nonetheless significant. The rapid 
decay is due to reaction with 02, lead- 
ing to production of NO~ and NO3, 
typically in amounts below the limit of 
detection. When stimulated with brady- 
kinin at 10 minute intervals, -N=O 
was released with each treatment, the 
amount released (between 70 pmol and 
approximately 0.7 nmol) being depen- 
dent on the concentration of brady- 
kinin used 12"14. The calcium ionophore 
A23187 is the only stimulant that leads 
to an extended release of .N=O (Ref. 
15); an immediate increase in .N=O 
decays slowly over the next 30 minutes. 
This is presumably due to an extended 
but decreasing rate of synthesis along 
with a continual decomposition 
reaction. 
A recent report is consistent with the 
generation of .N=O in the rat cerebel- 
lum after stimulation of N-methyl- 
D-aspartate receptors I~'. Nitric oxide 
was not measured directly, but the 
indirect experiments are all consistent 
with the chemical properties of .N=O. 
The burst of .N= O formation is similar 
to that observed in endothelial cells. 
Substrate, products and inhibitors 
When activated macrophages were 
placed in media that lacked all free 
amino acids, synthesis of NO2 and 
NO~ was 25-30% of that obtained in 
the normal media. The only amino acid 
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H 2 N ~ N H 2  H2N + .NH_CH 3 
L/ COO - H3+ COO 
N H3 ÷ NG.monomethyl. 
L-homoarginine L-arginine 
H 2 N ~ N H - O H  H 2 N - . ' ~ < .  - N H 2 
H3 COO - H 3 COO - 
+ + 
NG-hydroxy-,-arginine L-eanavanine 
bTg. 1. Substrates (left) and inhibitors (righO o f  
• N=O,  N O ,  and NO2i formation. See text for  
derails. 
that restored the synthesis of NO2 and 
NO? was L-arginine. In fact, L-arginine 
at 2 mN gave 120% the value obtained 
with the amino acid complete media 
that contains 0.6 mM l,-arginine. No 
other naturally occurring amino acid 
was shown to be a substrate 5. The back- 
ground synthesis obtained in the amino 
acid free medium is probably derived 
from endogenous arginine, and results 
with varying concentrations of [15N]- 
arginine are consistent with this con- 
clusion 7. Studies with 14C-labeled 
L-arginine showed that citrulline was 
the other product of the reaction 7 and 
although the stereochemistry at the 
{,-carbon was never determined, it has 
been assumed not to change. No inter- 
mediates involving the amino acid 
backbone were observed. In addition, 
NH3 and NH2OH were not substrates, 
ruling out the speculation that the path- 
way involved hydrolysis of L-arginine 
to citrulline and NH3 followed by the 
oxidation of NH3 to NO5 and NO? 
(Ref. 11). The enzyme catalysing this 
hydrolysis reaction, arginine deimi- 
dase, has never been reported in mam- 
malian tissues. The reaction seems to 
be quite specific for L-arginine. Equi- 
molar concentrations of L-homoargi- 
nine (Fig. 1) are about 80% as efficient 
for NO2 and NO~ synthesis 7. I>Argi- 
nine is not a substrate nor does it inhibit 
the reaction 7"m either in vivo or in a 
cell-free system, thus ruling out the 
possibility of the inability of I)-arginine 
to enter the cell. Moncada and col- 
leagues have shown that the .N= O pro- 
duced from endothelial cells is de- 
rived from the same guanidino nitrogens 
of >-arginine 15. These experiments 
again utilized L-[guanidino-15N2] - 
arginine with bradykinin stimulation. 
A limited number of compounds 
have been studied as potential inhibi- 
tors of this reaction. Hibbs and co- 
workers were the first to show that a 
monomethylated arginine analogue, 
NC-monomethyl-L-arginine (Fig. 1) 
inhibited NO2 formation in macro- 
phages 11 . The inhibition in the cell free 
activity from macrophages was 50% at 
130 laM (Ref. 8). This compound was 
shown to have a similar inhibitory 
effect in endothelial cells is. In contrast, 
I,-canavanine, a fairly broad inhibitor 
of arginine-utilizing reactions, inhibits 
NO2 and NO3 synthesis in macro- 
phages 7 but has no effect on the reac- 
tion in endothelial cell cultures 15 or 
homogenates ~7. Thus, although the 
pathway of .N=O formation in the two 
cell types seems to be identical there 
may be subtle differences in the 
enzymes involved. The major differ- 
ence between the two cell types seems 
to be in the regulation of the biosyn- 
thetic pathway, which may be related 
to physiological function. 
Current status o f  the enzymology 
Although some progress has been 
made, the molecular mechanisms of 
this unusual oxidation of arginine 
remain largely unknown. The enzyme 
activity in macrophages and endo- 
thelial cells is found in the cytosolS'~7; 
activity was recovered exclusively in 
the 100 000 g supernatant in subcellular 
fractionation experiments. In addition, 
reducing equivalents are required in 
broken cell preparations. NADPH,  but 
not NADH or ascorbic acid, will sup- 
port the oxidation of arginine to citrul- 
line and .N=O with subsequent 
decomposition of the -N=O to NO7 
and NO~ (Ref. 8). Supernatant from 
non-activated RAW 264.7 cells was 
completely inactive. The activity in 
endothelial cell 100 000 g supernatant 
also required NADPH and was 
inhibited by NC-monomethyl-L - 
arginine 17. 
All the evidence suggested that the 
first step of the reaction pathway was 
the hydroxylation of arginine at one of 
two equivalent guanidino nitrogens 
forming NC-hydroxy-L-arginine (Fig. 
1). A synthetic version of this com- 
pound (Nanjappan, Woodard and 
Marietta, unpublished), has been 
shown to be a substrate for the reaction 
leading to NO2, NO? and citrulline in a 
cell-flee system (Pufahl, Tayeh, Nan- 
jappan, Woodard and Marietta, un- 
published). The reaction also required 
NADPH. NG-Hydroxy-L-homoargi - 
nine was also synthesized and found to 
be a substrate. 
A proposed scheme that is consistent 
with all the evidence obtained to date is 
shown in Fig. 2 (Ref. 8). The first step 
illustrates the hydroxylation of argi- 
nine yielding N%hydroxy-t-arginine. 
Although steps 2-5 are speculative, 
they do provide a chemically reason- 
able pathway to give the final products 
of the reaction, citrulline, NO2 and 
NO3. Step 2 simply shows a two- 
electron oxidation of the hydroxyl- 
amine moiety, a common reaction for 
this relatively unstable functional 
group, producing N%oxo-L-arginine. 
The electron acceptor in this reaction is 
presently unknown. This product could 
also be formed by a second hy- 
droxylation upon N%hydroxy-e-argi- 
nine followed by a dehydration. This 
would explain the need for additional 
NADPH when N~-hydroxy-L-arginine 
is used as a substrate. The attractive 
feature of the third step is that, by 
simple loss of a hydrogen atom, the 
amino acid radical generated would be 
expected to be very unstable and 
should fragment as indicated in step 4 
to yield .N=O and an amino acid car- 
bodiimide. This compound, N-[(2- 
amino)-valeryl]-carbodiimide, would 
be expected to react with H20 in a 
manner typical of carbodiimides to 
yield, in this particular case, citrulline. 
Early efforts directed toward the 
purification of the enzyme(s) involved 
in this reaction pathway were ham- 
pered by the apparent instability of the 
activity. A series of experiments 
showed that this loss of activity was not 
due to enzyme instability, but to the 
loss of a low molecular weight cofactor, 
recently shown to be tetrahydrobio- 
pterin ~s. Arginine loss and product for- 
mation are dependent on tetrahydro- 
biopterin. The other three mammalian 
tetrahydrobiopterin-requiring hydrox- 
ylases (phenylalanine-, tyrosine- and 
tryptophan-hydroxylase) all carry out 
reactions at aromatic carbons and so 
these results suggest a novel hydrox- 
ylation for tetra-hydrobiopterin at a 
guanidino nitrogen. 
Biological function of nitric oxide 
generation 
The proposals regarding the biologi- 
cal role for -N=O have mainly centered 
around the enzyme guanylate cyclase. 
This enzyme catalyses the conversion 
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of GTP to cyclic GMP (cGMP). It had 
been known for some time., that . N = O  
was capable of activating guanylate 
cyclase leading to a substantial increase 
in cGMP levels a9. Other compounds 
that activate guanylate cyclase include 
NAN3, NH2OH, NaNO2, nitroglycerin 
and sodium nitroprusside. Under  bio- 
logical conditions all these agents are 
capable of generating .N=O.  The 
enzyme is ubiquitous and exists in both 
soluble and particulate (membrane 
bound) forms. Both forms are gener- 
ally found in the same cell, although the 
amounts and subcellular localization 
vary from cell to cell and are influenced 
by the particular physiological state of 
the cell. The soluble enzyme has been 
purified to homogeneity from a number 
of sources and, consequently, has 
received more attention than the par- 
ticulate form. The purified soluble 
enzyme will bind a hem.s prosthetic 
group and the reaction of . N = O  with 
iron proteins, particularly hemo- 
proteins, is well known 2°. Evidence 
suggests that binding of .N=O to the 
heme plays a direct role in the acti- 
vation of the enzyme. The key exper- 
iments supporting the . N = O - h e m e  
interaction model have come from a 
number of laboratories and show that 
some purification procedures can lead 
to the loss of the prosthetis heme with 
resulting loss in the ability to be acti- 
vated by . N = O  and related agents. 
However,  reconstitution ef the heme- 
depleted enzyme with hematin and 
reducing agents, typically thiols, leads 
to enzyme that can once again be stim- 
ulated by . N=O generating com- 
pounds 19. The amount of activation is 
dependent  on the source of the enzyme 
and ranges from 10- to 50-fi)ld. It is also 
clear that activation of guanylate 
cyclase involves thiols on the enzyme 
and the evidence taken together 
suggests oxidation/reduction processes 
that are linked to the basal and acti- 
vated activity of the enzyme. Guan- 
ylate cyclase shows high-affi nity binding 
for heme 2l, and studies concerning the 
physiological importance of this are 
continuing. 
The role of cGMP as a second mes- 
senger is not as well developed as that 
for another cyclic nucleotide, cAMP. 
However,  over the last 5-10 years 
cGMP has assumed a more prominent 
role as second messenger, in particular, 
increases in cGMP have been associ- 
ated with smooth muscle relaxation. 
Alterations in Ca 2+ levels induced by 
cGMP ultimately control smooth 
muscle tension. Several laboratories 
4- H2N ~,,~" N H2 
NH 
H 3 COO 
c-arginine 









[ ]  N=C=NH 
HsN~COO - 
Fig. 2. Reaction scheme (steps 1-5) for the conver- 
sion of  ~-arginine to -N-O,  NO2, NO3 and 
citrulline. 
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showed that the nitrovasodilators, such 
as nitroglycerin, produce an increase in 
cGMP levels in smooth muscle tissue 
and, as mentioned above, these nitro- 
vasodilators can activate the enzyme 
guanylate cyclase through the gener- 
ation of .N=O.  Thus, nitrovasodilators 
might simply circumvent the gener- 
ation of .N =O  from arginine and pro- 
duce • N = O  directly. Taken together,  
these findings suggest that at least one 
physiological role of the arginine path- 
way is to activate guanylate cyclase 
leading to an increase in the second 
messenger cGMP. Other recent results 
support this proposed role including 
those of Garthwaite and colleagues 16 
who showed that glutamate induced 
the release of a diffusible messenger 
that had chemical properties very simi- 
lar to .N=O.  This appears to be 
another example of intercellular com- 
munication where the intracellular sig- 
nal is cGMP whose level is increased 
via the activation by .N=O.  It has long 
been known that in the central nervous 
system, and especially in the cerebel- 
lum, the excitatory neurotransmitter 
glutamate can elicit large increases in 
cGMP levels. 
What, then, is the role of .N =O  pro- 
duction in the macrophage? There are 
two major possibilities. The killing and 
cytostasis-inducing functions of acti- 
vated macrophages might suggest that, 
through its chemical properties, .N =O  
is acting as a cytotoxic agent. Hibbs and 
colleagues have reported that L-argi- 
nine is required for activated macro- 
phages to induce cytostasis in target 
tumor cell lines 1°. Furthermore,  they 
have recently reported 9 that the same 
pattern of metabolic inhibition induced 
by macrophages in the tumor cell line 
can be reproduced directly by .N--O. 
On the other hand, it is known that 
cyclic nucleotides are involved in the 
regulation of several macrophage func- 
tions including phagocytosis, motility, 
response to lymphokines and DNA 
synthesis and it has been reported that 
macrophages treated with -N=O 
generating agents show a large increase 
in cGMP levels 22. This would suggest 
that macrophage killing/cytostatic 
properties might be cGMP dependent  
and that the .N =O  synthesized is used 
to elevate intracellular cGMP levels. 
The involvement of .N =O as a key 
metabolite in the activation of the 
enzyme guanylate cyclase represents a 
novel control mechanism. The bio- 
chemistry of the pathway o f .N  = O pro- 
duction including the oxidation of 
e-arginine at the guanidino nitrogen 
will no doubt involve some novel enzy- 
mology that has already begun to 
unfold. The understanding of this enzy- 
mology and regulation of this pathway 
will ultimately lead to agents specifi- 
cally designed for the rational control 
of -N=O formation. The pharmaco- 
logical potential for these new agents is 
promising. 
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H a e m  as  a multifunctional  
regulator 
G. Padmanaban, V. Venkateswar and P. N. Rangarajan 
Haem has long been known as the prosthetic group o f  haemoproteins such as 
haemoglobin, catalase and the cytochromes. Its biosynthesis is regulated by feed- 
back mechanisms that ensure its adequate production but prevent its overaccumu- 
lation, which is highly deleterious as diseases such as porphyrias attest. However, 
recent years have seen rapid strides in our understanding o f  how haem (or more 
accurately haemin, its oxidized form) itself acts as an intracellular regulator of  a 
w riety of  other metabolicpathwaysfor systems that utilize oxygen. 
Haem dynamics in the cell 
The haem biosynthetic pathway has 
been demonstrated in a wide variety of 
living systems. However,  most infor- 
mation on haem dynamics has been 
obtained with liver cells. It is estimated 
that 1 ml of marrow erythroblasts can 
make 6100 nmol ~-aminolevulinate 
( A L A )  h -1 .  (ALA is the first commit- 
ted precursor of the haem biosynthetic 
pathway, see Fig. 1.) In liver, ALA is 
made at a rate of 20-25 nmol (g liver) 1 
h - t ,  about 15% of that of whole bone 
marrow. In liver ALA is quantitatively 
converted to haem. The total haem 
content of liver is estimated to be 2.6 
nmol g 1 and nearly 65% of it is used to 
replenish cytochrome P-450 haem. The 
'free and exchangeable' haem pool is 
thought to be in the range of 10-100 
nM. Fluctuations beyond this range 
bring about a rapid alteration in the 
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levels of haem biosynthetic and degra- 
dative enzymes 1. 
Haem is synthesized in the mito- 
chondrion and is then distributed to the 
different haemoproteins located in 
mitochondria, microsomes, peroxi- 
somes and cytosol. The mechanism of 
intracellular transport of haem is not 
very clear. There is some evidence sup- 
porting the concept of cytoplasmic 
haem carriers transporting haem from 
mitochondria to other locations. Ultra- 
structural studies have revealed the 
presence of rough endoplasmic 
reticulum-mitochondrion (RERM) 
complexes in the liver cell, and it has 
been suggested that these complexes 
would facilitate the integration of haem 
made in mitochondria with the apo- 
cytochrome synthesized on the rough 
endoplasmic reticulum 2. Haem is also 
implicated in transcriptional regulation 
(see below), and so transport into the 
nucleus to form a regulatory pool is 
likely. 
Although the bulk of the haem of the 
liver cell is synthesized in situ, some 
© 1989, Elsevier Science Publishers Ltd, [UK) 0376 5067/89/$02.011 
also reaches the liver as haptoglobin- 
haemoglobin and haem-haemopexin 
complexes, arising out of intravascular 
hemolysis of senescent red cells. 
Uptake by the liver is mediated by 
specific receptors. There is evidence 
that haem from haem-haemopexin 
reaches several target sites including 
the liver nucleus 3. It is not clear 
whether the newly biosynthesized 
haem mixes with the haem derived 
from red cells or whether separate 
pools are maintained. However,  it 
appears that both should be contribu- 
ting to the regulatory pool, since haem- 
regulated proteins are responsive to 
haem levels generated in the mitochon- 
drion as well as to exogenous haem. 
Haem regulates its own biosynthesis 
The two crucial enzymes involved in 
regulating the levels of intracellular 
haem in liver are ALA synthetase 
(ALAS) and haem oxygenase I. ALAS 
is induced by a wide variety of chemi- 
cals and suppressed by the administra- 
tion of haem. There is good evidence 
that haem negatively regulates the syn- 
thesis of ALAS 4. With the use of 
cloned cDNA, it has been shown in rat 
liver that haemin (the oxidized form of 
haem), actinomycin D and ct-amanatin 
bring about a rapid decrease in the 
intracellular levels of ALAS mRNA, 
pre-induced by 2-ailylisopropylacet- 
amide. Since there is no change in the 
half-life of ALAS mRNA under these 
conditions, haemin most likely 
represses the transcription of the 
gene 5. Earlier, this laboratory had pro- 
posed a positive regulatory model, 
where ALAS induction could be posi- 
tively modulated by apo-cytochromc 
P-450, the effect ceasing with thc for- 
mation of the holoprotein 6. Haem 
